Intelligence feed
Reviewed study and trial updates will appear here as our editors publish them. Below: FDA and regulatory changes already verified for our tracker.
Same story: these are recommendations, not approvals. None of these peptides is an approved medicine.
What this doesn't mean: A 'yes' vote is not approval and does not yet permit compounding; a 'no' vote is not a safety finding against a substance.
A “yes” is advice to FDA, not approval. Nothing changes until FDA writes a formal rule — which could take years.
What this doesn't mean: Advisory votes are recommendations. FDA must complete rulemaking before any of these can be lawfully compounded, and inclusion on the bulks list is not drug approval.
Taking them off that list doesn’t approve them or let pharmacies make them yet — it moves them into review.
What this doesn't mean: Removal from Category 2 does not make a substance eligible for compounding, and it is not FDA approval.
How this feed works: candidates are gathered automatically from PubMed, ClinicalTrials.gov and FDA press releases. A person opens each one, writes the headline in plain English and approves it; the database won't let anything publish without that step. Methodology